August 3rd, 2010
Building on Your Success
Harlan M. Krumholz, MD, SM
Welcome to the remodeled CardioExchange: We hope you like our new look! In our efforts to develop a website that promotes learning and discussion about our rapidly evolving field, we’ve been listening and learning.
We have many new features. Some of the most prominent are:
- You can now see all of the activity on the site from the new homepage, including newly uploaded posts and comments.
- You can now make anonymous comments. Many people think this may foster more discussion. We are eager to see whether that happens.
- You can now “follow” the people, blogs, and topics that interest you the most and receive email notifications when new activity takes place.
With all these changes, our philosophy and approach remain the same. We want to be a credible, trustworthy source of information and a venue for the exchange of views and perspectives. We want to give you access to the various ways people are thinking about new (and old) information in medicine — and provide you the opportunity to learn from each other.
And we are not done listening. We will continue to learn from what you say on and do with CardioExchange, as well as from your direct feedback. Ultimately, the site is a facilitator; it is the people who make CardioExchange. We will be encouraging you to be more involved and to try out the various features. And we ask you to bring in others to participate. The site ultimately belongs to the community — and it is up to all of us to define it.
Categories: General
Tags: CardioExchange, social media
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
-
Search the Archive
Archives by Date
NEJM — Recent Cardiology Articles- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026In patients with atrial fibrillation and a stent placed at least 1 year earlier, non–vitamin K antagonist oral anticoagulant monotherapy resulted in fewer net adverse clinical events at 2 years than a NOAC plus clopidogrel.
- Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI November 19, 2026Among patients with STEMI, prasugrel monotherapy initiated before PCI was not noninferior to dual antiplatelet therapy with prasugrel plus aspirin for a composite of death, stroke, or myocardial infarction at 12 months.
- Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke November 19, 2026In 2015, pivotal randomized, controlled trials established the benefit of endovascular treatment for acute ischemic stroke due to a large-vessel occlusion.1,2 The trials showed a major clinical benefit in patients presenting with relatively standard stroke features: large-vessel occlusion in the anterior circulation; relevant clinical neurologic deficit; short time...
- Too Soon to Say Goodbye — Aspirin at the Door in STEMI November 19, 2026The 19th-century English biologist Thomas H. Huxley once said, “The great tragedy of Science — the slaying of a beautiful hypothesis by an ugly fact.” For as long as many can recall, aspirin has been the first drug administered for the treatment of ST-segment elevation myocardial infarction (STEMI), often in...
- Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke November 19, 2026Among patients with salvageable tissue 24 to 72 hours after stroke, physical function at 90 days was better with thrombectomy than with medical care alone, but intracerebral hemorrhage and death were more common with thrombectomy.
- Extended Outcomes of the ADAPT AF-DES Trial November 19, 2026
-
Tag Cloud
- ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
